SUPPLEMENTARY FUNDING OFFER FOR THE MRC UNIT, THE GAMBIA AT LSHTM (resource to support a clinical trial of Hydroxychloroquine and Azithromycin, studies on the transmission and antibody dynamics to SARS-CoV-2 infection, and to further support
Lead Research Organisation:
London School of Hygiene and Tropical Medicine
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
This £4.4m award provides resource to support a clinical trial of Hydroxychloroquine and Azithromycin, studies on the transmission and antibody dynamics to SARS-CoV-2 infection, and to further support surveillance activities funded by BMGF.
Including
PaTS-COVID CLINICAL TRIAL – led by Professor Beate Kampmann with an end date 31/12/2023
The TransVir project – led by Dr Anna Roca with an end date 30/06/2023
Including
PaTS-COVID CLINICAL TRIAL – led by Professor Beate Kampmann with an end date 31/12/2023
The TransVir project – led by Dr Anna Roca with an end date 30/06/2023
Publications
Bonell A
(2021)
Impact of Personal Cooling on Performance, Comfort and Heat Strain of Healthcare Workers in PPE, a Study From West Africa.
in Frontiers in public health
Brotherton H
(2020)
Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa
in The Lancet Global Health
Citarella BW
(2024)
Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms.
in Heliyon
Diallo BA
(2022)
Clinical research on COVID-19: perceptions and barriers to participation in The Gambia.
in BMJ global health
Jarju S
(2024)
High SARS-CoV-2 incidence and asymptomatic fraction during Delta and Omicron BA.1 waves in The Gambia.
in Nature communications
| Description | Ivermectin, a potential treatment for COVID-19 patients, did not show any therapeutic effect. We also investigated aspirin and high dose corticosteroids as potential treatment. However, the number of patients recruited were lower than expected. |
| Exploitation Route | Outcomes show that several candidate treatments for COVID-19 were not efficacious. |
| Sectors | Pharmaceuticals and Medical Biotechnology |
| Description | The trial investigated the treatment of several treatment option for mild and severe Covid-19. Results contributed to define treatment guidelines for these patients. |
| First Year Of Impact | 2022 |
| Sector | Pharmaceuticals and Medical Biotechnology |
| Impact Types | Policy & public services |
| Description | COVID-19 STRATEGIC COORDINATION MEETING |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | Coordination of Covid-19 public health interventions. |